Context Therapeutics (CNTX) Competitors

Context Therapeutics (NASDAQ:CNTX) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, community ranking, earnings, valuation, risk and media sentiment.

Which has better earnings and valuation, CNTX or GRFS?

Grifols has higher revenue and earnings than Context Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Context Therapeutics	N/A	N/A	-$23.96M	-$1.33	-1.35
Grifols	$7.13B	N/A	$64.20M	N/A	N/A

Does the media favor CNTX or GRFS?

In the previous week, Context Therapeutics had 4 more articles in the media than Grifols. MarketBeat recorded 11 mentions for Context Therapeutics and 7 mentions for Grifols. Context Therapeutics' average media sentiment score of 0.96 beat Grifols' score of 0.25 indicating that Context Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Context Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Grifols	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more volatility & risk, CNTX or GRFS?

Context Therapeutics has a beta of 2.14, suggesting that its stock price is 114% more volatile than the S&P 500. Comparatively, Grifols has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500.

Is CNTX or GRFS more profitable?

Grifols has a net margin of 0.90% compared to Context Therapeutics' net margin of 0.00%. Grifols' return on equity of 1.73% beat Context Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Context Therapeutics	N/A	-136.03%	-109.54%
Grifols	0.90%	1.73%	0.66%

Does the MarketBeat Community prefer CNTX or GRFS?

Grifols received 334 more outperform votes than Context Therapeutics when rated by MarketBeat users. However, 66.67% of users gave Context Therapeutics an outperform vote while only 55.95% of users gave Grifols an outperform vote.

Company	Underperform	Outperform
Context Therapeutics	Outperform Votes 14 66.67%	Underperform Votes 7 33.33%
Grifols	Outperform Votes 348 55.95%	Underperform Votes 274 44.05%

Do insiders & institutionals have more ownership in CNTX or GRFS?

14.0% of Context Therapeutics shares are owned by institutional investors. 9.4% of Context Therapeutics shares are owned by insiders. Comparatively, 0.2% of Grifols shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Do analysts prefer CNTX or GRFS?

Context Therapeutics currently has a consensus target price of $6.00, indicating a potential upside of 233.33%. Grifols has a consensus target price of $10.50, indicating a potential upside of 36.90%. Given Context Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Context Therapeutics is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Context Therapeutics	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Grifols	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

Context Therapeutics beats Grifols on 9 of the 15 factors compared between the two stocks.